DUPIXENT (Sanofi-Aventis Australia Pty Ltd)
Product name
DUPIXENT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
dupilumab (rch)
Registration type
NCE/NBE
Indication
DUPIXENT is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.